Medimmune's interim president assumes full role
US-based biotech business MedImmune has welcomed the appointment of Tony Zook as its new president.
US-based biotech business MedImmune has welcomed the appointment of Tony Zook as its new president.
Zook, who led the company on an interim basis, will continue to lead the company - a wholly owned biologics business for AstraZeneca PLC as well as taking responsibility for AstraZeneca's US and Canadian businesses and the company's global marketing organisation.
"I am pleased to continue working with the leadership team here at MedImmune to advance our strategic plan to discover, develop and deliver innovative biologic treatments that can positively impact patient health," said Zook.
The biotech company, which is headquartered in Gaithersburg, Maryland, is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience.
